Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each

Dow Jones04-16

By Colin Kellaher

Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.

At the $16 midpoint of that range, the Fremont, Calif., proteomics company said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.

Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.

The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 16, 2026 10:41 ET (14:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627211129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627211129","market":"sg","top_or_hot":-1,"title":"Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-16 22:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627211129","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627211129","pubTimestamp":1776350460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","SPCX":"SPAC and New Issue ETF","ALMR":"Alamar Biosciences, Inc."},"translate_title":"Alamar Biosciences将IPO规模定为940万股，每股定价为15-17美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"ALMR":1.5,"SPCX":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n\n\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n\n\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n\n\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 10:41 ET (14:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627211129","isCrawlerRequest":true}